

# Lucas Boeck

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3086161/publications.pdf>

Version: 2024-02-01

18  
papers

350  
citations

840119

11  
h-index

1125271

13  
g-index

21  
all docs

21  
docs citations

21  
times ranked

635  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute Effects of Aerosolized Iloprost in COPD Related Pulmonary Hypertension - A Randomized Controlled Crossover Trial. PLoS ONE, 2012, 7, e52248.	1.1	48
2	Pancreatic Stone Protein. Chest, 2011, 140, 925-932.	0.4	43
3	Mortality risk prediction in COPD by a prognostic biomarker panel. European Respiratory Journal, 2014, 44, 1557-1570.	3.1	43
4	Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index. European Respiratory Journal, 2014, 43, 397-408.	3.1	41
5	Prognostic assessment in COPD without lung function: the B-AE-D indices. European Respiratory Journal, 2016, 47, 1635-1644.	3.1	37
6	Therapy with protonâ€pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology, 2016, 21, 883-890.	1.3	32
7	Single-Breath Washout Tests to Assess Small Airway Disease in COPD. Chest, 2016, 150, 1091-1100.	0.4	29
8	The Sequential Organ Failure Assessment score and copeptin for predicting survival in ventilator-associated pneumonia. Journal of Critical Care, 2012, 27, 523.e1-523.e9.	1.0	21
9	Exertional Hypoxemia in Stable COPD Is Common and Predicted by Circulating Proadrenomedullin. Chest, 2014, 146, 328-338.	0.4	20
10	Vasoactive Intestinal Peptide for Diagnosing Exacerbation in Chronic Obstructive Pulmonary Disease. Respiration, 2015, 90, 357-368.	1.2	14
11	Longitudinal Measurement of Serum Vascular Endothelial Growth Factor in Patients with Chronic Obstructive Pulmonary Disease. Respiration, 2015, 90, 97-104.	1.2	13
12	Adenovirus-Specific IgG Maturation as a Surrogate Marker in Acute Exacerbations of COPD. Chest, 2014, 146, 339-347.	0.4	4
13	Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD. Pulmonary Pharmacology and Therapeutics, 2018, 48, 111-116.	1.1	4
14	Hyaluronic acid as a novel systemic biomarker to predict progression and severity in chronic obstructive pulmonary disease. , 2016, , .		1
15	Circulating vasoactive intestinal peptide for diagnosis of exacerbation of COPD. , 2015, , .		0
16	Hyaluronic acid, heparan sulfate and chondroitin sulfate are altered during exacerbations of COPD. , 2017, , .		0
17	Irisin is associated with clinical outcomes and up-regulated by long-acting anticholinergics in COPD. , 2017, , .		0
18	Longitudinal profiling of viral infections in COPD patients and their implication to exacerbations. , 2018, , .		0